Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | TNKS | O95271 | 3/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.44 |
| ▸ | PDE5A | O76074 | 4/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4141949 | 0.99 | FGFR1 (0.45) | FGFR1FGFR2BRD4TNKSTNKS2 | |
| SCHEMBL4144759 | 0.80 | CDKN1A (0.38) | FGFR1FGFR2PARP1ALDH1A1GAA | |
| SCHEMBL4148644 | 0.79 | KDM4E (0.66) | FGFR1FGFR2BRD4TNKSTNKS2 | |
| SCHEMBL4143684 | 0.77 | PARP1 (0.43) | FGFR1FGFR2BRD4TNKS2L3MBTL1 | |
| SCHEMBL10150419 | 0.76 | KDM4E (0.62) | FGFR1FGFR2BRD4TNKSTNKS2 | |
| SCHEMBL8885602 | 0.72 | GABRA3 (0.51) | — | |
| SCHEMBL3722376 | 0.72 | PDE5A (0.58) | FGFR1FGFR2PDE5AAURKADCUN1D1 | |
| SCHEMBL15145603 | 0.72 | PDE5A (0.50) | FGFR1FGFR2PDE5AAURKAL3MBTL1 | |
| SCHEMBL4155773 | 0.72 | L3MBTL1 (0.38) | FGFR1FGFR2TNKS2L3MBTL1PARP1 | |
| SCHEMBL4147913 | 0.71 | L3MBTL1 (0.54) | FGFR1FGFR2PDE5AAURKAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| EP-1951244-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062370-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | CALCR, SOST, CALCB | FGFR1 2632/4885FGFR2 2404/4885BRD4 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.